BackAkero Therapeutics Overview

Akero Therapeutics Other Liabilities

Latest other liabilities for AKRO: $0.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

Akero Therapeutics Other Liabilities History

Loading

Akero Therapeutics vs. peers: Other Liabilities Comparison

Loading

Akero Therapeutics Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Akero Therapeutics (AKRO) FAQ

As of the most recent data (September 2025), AKRO shows a other liabilities of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AKRO's other liabilities is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Akero Therapeutics is outperforming or lagging.

Tracking AKRO's other liabilities over time shows whether Akero Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other liabilities page, Stockcircle has Akero Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other liabilities (currently $0) with ownership activity and broader fundamentals.

Akero Therapeutics's other liabilities is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.